Abstract
Hepatocellular carcinoma (HCC) is a leading cause of cancer related death both in the United States and worldwide. Proper management begins with identification of high risk individuals who may benefit from a screening program for HCC, since early detection of this cancer can lead to improved survival. Advances in radiographic technology and new staging systems that take tumor burden and clinical status into account allow patients to be more accurately stratified into proper treatment groups. Depending on the cancer stage, treatments such as radiofrequency ablation (RFA), surgical resection and liver transplantation offer a potential cure, while other treatments such as transarterial chemoembolization (TACE) can prolong life with HCC. New agents such as the oral multikinase inhibitor sorafenib show promise of slowing disease through utilization of molecular targeting. In this article, we will review management strategies of HCC, from diagnosis to treatment.
Keywords: Hepatocellular carcinoma, therapy, liver transplantation, diagnosis
Current Cancer Therapy Reviews
Title: Current Treatment Strategies for Hepatocellular Carcinoma
Volume: 6 Issue: 3
Author(s): Andrew Aronsohn and Smruti R. Mohanty
Affiliation:
Keywords: Hepatocellular carcinoma, therapy, liver transplantation, diagnosis
Abstract: Hepatocellular carcinoma (HCC) is a leading cause of cancer related death both in the United States and worldwide. Proper management begins with identification of high risk individuals who may benefit from a screening program for HCC, since early detection of this cancer can lead to improved survival. Advances in radiographic technology and new staging systems that take tumor burden and clinical status into account allow patients to be more accurately stratified into proper treatment groups. Depending on the cancer stage, treatments such as radiofrequency ablation (RFA), surgical resection and liver transplantation offer a potential cure, while other treatments such as transarterial chemoembolization (TACE) can prolong life with HCC. New agents such as the oral multikinase inhibitor sorafenib show promise of slowing disease through utilization of molecular targeting. In this article, we will review management strategies of HCC, from diagnosis to treatment.
Export Options
About this article
Cite this article as:
Aronsohn Andrew and R. Mohanty Smruti, Current Treatment Strategies for Hepatocellular Carcinoma, Current Cancer Therapy Reviews 2010; 6 (3) . https://dx.doi.org/10.2174/157339410791698151
DOI https://dx.doi.org/10.2174/157339410791698151 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chronic Kidney Disease and Urological Disorders: An Overview
Current Signal Transduction Therapy Evaluation of Endothelial (dys)Function, Left Ventricular Structure and Function in Patients with Chronic Kidney Disease
Current Vascular Pharmacology Biological Markers in Older People at Risk of Mobility Limitations
Current Pharmaceutical Design Hepatotoxic Effect of <i>Lafoensia pacari</i> A. St. Hil. (Lythraceae) on a Diet-Induced Obese Mice Model
Protein & Peptide Letters Prognostic Value of Copeptin in Chronic Kidney Disease: From General Population to End-Stage Renal Disease
Current Protein & Peptide Science Vitamin D Supplementation: A Promising Approach for the Prevention and Treatment of Strokes
Current Drug Targets A<sub>3</sub> Adenosine Receptor: A Plausible Therapeutic Target for Cardio-Protection in Diabetes
Recent Patents on Cardiovascular Drug Discovery Clinical Pharmacology of Trastuzumab
Current Clinical Pharmacology Does the Acupoint Specificity Exist? Evidence from Functional Neuroimaging Studies
Current Medical Imaging Obesity and Cardioprotection
Current Medicinal Chemistry Epigenetic Regulation Through SIRT1 in Podocytes
Current Hypertension Reviews Vascular Toxicity of Chemotherapeutic Agents
Current Vascular Pharmacology Aquaporins as Targets for Drug Discovery
Current Pharmaceutical Design Editorial (Thematic Issue: Switching to Biological Agents in Autoimmune and Autoinflammatory Disorders: Current Targets and Therapy)
Current Medicinal Chemistry Delirium Secondary to Lamotrigine Toxicity
Current Drug Safety The Bioactive Compounds Obtained from Hawthorn, Chokeberry, Rosehip and Bilberry by Microfiltration
Current Bioactive Compounds The Heart and Brain Imaging in Lone Atrial Fibrillation – Are We Surprised?
Current Pharmaceutical Design Downregulation of Hepatic Carbonyl Reductase Type 1 in End-Stage Renal Disease
Drug Metabolism Letters The Treatment of Behavioral and Psychological Symptoms of Dementia: Weighing Benefits and Risks
Current Alzheimer Research Primary Hyperaldosteronism in the Hypertensive Disease
Current Hypertension Reviews